Skip to main content
Premium Trial:

Request an Annual Quote

Bioneer Develops Ebola MDx Kit in Partnership with Nigerian Biotech Agency

NEW YORK (GenomeWeb) — South Korean molecular diagnostics firm Bioneer announced on Wednesday the availability of a molecular test kit for the Ebola virus that it has developed in collaboration with the Nigerian National Biotechnology Development Agency (NABDA).

Specifically, the company's AccuPower EBOV real-time RT-PCR kit is optimized for detection of the Zaire subtype of the Ebola virus associated with recent outbreaks in Africa. Bioneer has worked with NABDA since April to develop means to rapidly detect this subtype.

The new kit is currently in limited use by NABDA, and Bioneer plans to make it available for use throughout Africa, a company spokesperson said.

Bioneer recently presented details about the kit at an Ebola virus-related workshop held by NABDA in Abuja, Nigeria, where the company trained symposium attendees on the firm's ExiStation real-time PCR system, as well as on the assay's use, outlining how it could provide early diagnosis of viral infection and quantitative analysis of viral load during treatment.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.